177Lu-PRRT in advanced gastrointestinal neuroendocrine tumors: 10-year follow-up of the IRST phase II prospective study.

Giovanni PaganelliMaddalena SansoviniSilvia NicoliniIlaria GrassiToni IbrahimElena AmadoriValentina Di IorioManuela MontiEmanuela ScarpiAlberto BongiovanniMattia AltiniLuca UrsoCorrado CittantiFederica MatteucciStefano Severi

Published in: European journal of nuclear medicine and molecular imaging (2020)

The long-term follow-up of the IRST phase II study shows that Lu-PRRT is a safe and effective therapy for patients with advanced GI-NET, the most important prognostic factor being tumor burden, hepatic lesions, and age. We believe that Lu-PRRT should be offered to patients with early-stage disease.

Keyphrases

phase ii study
phase ii
open label
prognostic factors
neuroendocrine tumors
early stage
clinical trial
placebo controlled
phase iii
locally advanced
study protocol
squamous cell carcinoma
double blind
risk factors
rectal cancer
radiation therapy
sentinel lymph node
neoadjuvant chemotherapy